GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a ...

The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...

GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...

IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.

Our Fool likes the look of these stock market juggernauts for the chunky passive income they throw off, not to mention their ...

The legal sector's engagement with the staggering potential of artificial intelligence has surprised long-time observers of ...

Nigeria’s pharmaceutical companies are ramping up investments and expanding operations to tap growing local opportunities.

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...

Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, ...

If automation is to become a key partner in experiment design and a core component of modern lab infrastructure, it is ...